Abstract 2358P
Background
Robotic total gastrectomy (RTG) is accepted as a safety approach to conventional laparoscopy total gastrectomy (LTG) for locally advanced gastric cancer. However, the long-term oncological efficacy of RTG remains unclear.
Methods
This prospective study included 48 patients with advanced proximal GC underwent RTG combined with spleen-preserving splenic hilar lymphadenectomy between March 2018 and February 2020. Patients who underwent LTG in the FUGES-002 study were enrolled in a 1:2 ratio to compare the outcomes between RTG and LTG. The primary outcome was overall postoperative morbidity rate. The secondary outcomes were three-year overall survival (OS), three-year disease-free survival (DFS), and recurrence patterns.
Results
After 1:2 propensity score matching, a total of 48 RTG and 96 LTG patients were included, with similar clinical and pathological data in both groups. In terms of surgical outcomes, the RTG group had significantly less intraoperative bleeding than the LTG group (66.4 vs. 38.7 ml, P = 0.042). With regard to lymph node dissection, the RTG group had a significantly higher number of non-gastric lymph node dissections than the LTG group (20.2 vs. 17.5, P = 0.039), and its lymph node metastasis rate was significantly lower than that of the LTG group (27.1% vs. 45.8%, P = 0.030); in terms of postoperative outcomes, the RTG group had significantly shorter times for first gas discharge, first out of bed, first liquid diet, first semi-liquid diet, and length of stay than the LTG group (P <0.05). Regarding long-term prognosis, the 3-year DFS of the RTG and LTG groups were 77.1% and 68.8%, respectively, and the 3-year OS were 85.4% and 74.0% (P >0.05 for both). Within 3 years after surgery, 9 (18.8%) and 27 (28.1%) patients in the RTG and LTG groups experienced recurrence, respectively, with similar recurrence patterns in both groups (P >0.05). There was no independent correlation between RTG and recurrence or gastric cancer-specific death (P >0.05 for both).
Conclusions
Among patients with a preoperative clinical stage indicating locally advanced gastric cancer, RTG, compared with LTG, did not result in inferior disease-free survival and overall survival at 3 years.
Clinical trial identification
The FUGES-014 was a prospective, single-arm, open-label study (NCT03524287) that was conducted at Fujian Medical University Union Hospital (FMUUH).
Editorial acknowledgement
Legal entity responsible for the study
Changming Huang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2325P - Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
Presenter: Rafael Rosell
Session: Poster session 16
2326P - Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy
Presenter: Michele Ghidini
Session: Poster session 16
2327P - The impact of the microenvironment on the intratumoral cellular heterogeneity in colorectal cancer
Presenter: Idan Carmi
Session: Poster session 16
2328P - Alternative molecular mechanisms underpinning breast invasive lobular carcinoma identified by genomics-driven artificial intelligence model
Presenter: Fresia Pareja
Session: Poster session 16
2329P - Evidence for the utility of artificial intelligence and image analysis in Ki-67 quantification in solid tumors
Presenter: Xavier Pichon
Session: Poster session 16
2331P - Interest of next generation sequencing (NGS) for integrated molecular diagnosis of HER2-low breast cancer
Presenter: Jean Louis Merlin
Session: Poster session 16
2332P - Overall survival in breast cancer patients with HER2-low status single- center experience
Presenter: Joanna Huszno
Session: Poster session 16
2333P - Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancers
Presenter: Anna Karlsson
Session: Poster session 16
2334P - Pathologic patterns following different neoadjuvant therapies in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster session 16